WCLC 2020: Datopotamab deruxtecan and Enhertu show promising clinical activity in patients with advanced non-small cell lung cancer

Lung cancer is the leading cause of cancer death, accounting for about one-fifth of all cancer deaths worldwide, of which 80-85% are classified as non-small cell lung cancer (NSCLC).
patients with metastasis, the prognosis was particularly poor, with only 6-10% of patients surviving within five years of diagnosis.
currently, there is no approved anti-NSCLC therapy targeting TRP2 or HER2.
latest data from AstraZeneca and AstraZeneca's Datapotamab deruxtecan (Dato-DXd; DS-1062) and Enhertu (Curto-Pearl monoantixtecan) show that both antibody drug conjugations (ADCs) have encouraging results for patients with late-stage NSCLC.
data were released during the World Lung Cancer Congress (WCLC).
results from the TRTPION-PanTumor01 Phase I trial showed good clinical activity in patients with late-stage or metastasis NSCLC targeting TRAP2.
addition, the results of the DESTINY-Lung01 Phase II clinical trial showed that metastasis NSCLC patients using Enhertu, which targeted HER2, had preliminary evidence of tumor resistance in HER2 over-expression queues.